1. Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma 
Owen J. Dempsey, MBChB, Gwen Kennedy, PhD, Brian J. Lipworth, MD 
Journal of Allergy and Clinical Immunology 
Volume 109, Issue 1, Pages (January 2002)
DOI: /mai
Copyright © 2002 Mosby, Inc. Terms and Conditions

2. Fig. 1
Effects on bronchial hyperresponsiveness: geometric mean “fold” differences (and 95% CIs) from placebo for inhaled corticosteroid and LTRA. *P < .05 versus placebo.
Journal of Allergy and Clinical Immunology  , 68-74DOI: ( /mai )
Copyright © 2002 Mosby, Inc. Terms and Conditions

3. Fig. 2
Effects on peak expiratory flow: means (and 95% CIs) for effects of placebo, LTRA, and inhaled corticosteroid on domiciliary peak flow. *P < .05 versus placebo. +P < .05 steroid versus LTRA.
Journal of Allergy and Clinical Immunology  , 68-74DOI: ( /mai )
Copyright © 2002 Mosby, Inc. Terms and Conditions

4. Fig. 3
Effects on surrogate inflammatory markers. Arithmetic means (and 95% CIs) are shown for all results except nitric oxide, for which geometric means are shown. *P < .05 versus placebo. +P < .05 steroid versus LTRA.
Journal of Allergy and Clinical Immunology  , 68-74DOI: ( /mai )
Copyright © 2002 Mosby, Inc. Terms and Conditions